Walleye Capital’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-10,800
Closed -$83.4K 4953
2025
Q3
$83.4K Buy
10,800
+8,100
+300% +$56.7K ﹤0.01% 3794
2025
Q2
$19.7K Sell
2,700
-26,800
-91% -$216K ﹤0.01% 4239
2025
Q1
$280K Buy
29,500
+27,300
+1,241% +$341K ﹤0.01% 3007
2024
Q4
$36.3K Sell
2,200
-3,400
-61% -$52.8K ﹤0.01% 4419
2024
Q3
$82.6K Buy
+5,600
New +$87.6K ﹤0.01% 4474
2023
Q2
Sell
-10,100
Closed -$176K 4698
2023
Q1
$176K Hold
10,100
﹤0.01% 2563
2022
Q4
$93.3K Buy
+10,100
New +$94.2K ﹤0.01% 2383
2019
Q4
Sell
-4,200
Closed -$80K 2099
2019
Q3
$80K Sell
4,200
-5,200
-55% -$122K ﹤0.01% 1490
2019
Q2
$206K Buy
+9,400
New +$206K 0.02% 948

Other funds holding NEO

Walleye Capital's NEO Position: Q4 2025 in Review

Walleye Capital sold out of NeoGenomics (NEO) in Q4 2025, closing a stake of 3,901 shares — an estimated $30.1K sold.

Walleye Capital first reported a position in NEO in Q2 2019 and held it in 9 quarters. The position peaked at $1.23M in Q1 2022. 256 funds tracked by Wall St. Rank hold NEO as of Q4 2025.

  • Walleye Capital reported no remaining NeoGenomics position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 3,901 NeoGenomics shares in Q4 2025, an estimated $30.1K.
  • Walleye Capital first reported a position in NeoGenomics in Q2 2019 and held it in 9 quarters.
  • Walleye Capital's NeoGenomics position peaked at $1.23M in Q1 2022.
  • 256 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.